FDA grants Breakthrough Therapy Designation for Roche's Gazyva (obinutuzumab) in Lupus Nephritis - GlobeNewswire

FDA grants Breakthrough Therapy Designation for Roche's Gazyva (obinutuzumab) in Lupus Nephritis  GlobeNewswire

There are currently no U.S. FDA-approved medicines for lupus nephritis; The designation is based on the results of the phase II NOBILITY study that showed ...